SAB Biotherapeutics (SABS) Leases (2020 - 2025)
Historic Leases for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $3.5 million.
- SAB Biotherapeutics' Leases fell 240.87% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 240.87%. This contributed to the annual value of $3.6 million for FY2024, which is 236.6% down from last year.
- Latest data reveals that SAB Biotherapeutics reported Leases of $3.5 million as of Q3 2025, which was down 240.87% from $3.5 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Leases registered a high of $4.0 million during Q4 2021, and its lowest value of $3.5 million during Q3 2025.
- For the 5-year period, SAB Biotherapeutics' Leases averaged around $3.7 million, with its median value being $3.7 million (2023).
- As far as peak fluctuations go, SAB Biotherapeutics' Leases tumbled by 583.07% in 2023, and later crashed by 236.6% in 2024.
- Over the past 5 years, SAB Biotherapeutics' Leases (Quarter) stood at $4.0 million in 2021, then dropped by 3.05% to $3.9 million in 2022, then fell by 5.83% to $3.7 million in 2023, then fell by 2.37% to $3.6 million in 2024, then fell by 1.82% to $3.5 million in 2025.
- Its Leases stands at $3.5 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.6 million for Q1 2025.